Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HitGen Closes $39 Million B Round for Drug Discovery/Development

publication date: May 28, 2018

HitGen, a Chengdu drug discovery/development company, closed a $39 million Series B financing led by CDH, a Beijing VC/PE firm, and Leadyond Capital, a PE firm also based in Beijing. So far, HitGen has established over 50 active drug discovery collaborations with pharmaceutical companies based on its DNA-encoded library, which consists of 900 individual libraries and over 200 billion novel small molecules. The company plans to use the proceeds to expand its drug discovery technology platform and accelerate the R&D of its in-house therapeutic development programs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital